Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: Interim results from 2 prospective phase 2 clinical trials

Cancer

Volumn 119, Issue 23, 2013, Pages 4111-4118

  Kong, Lin ^a   Hu, Chaosu ^a   Niu, Xiaoshuang ^a   Zhang, Youwang ^a   Guo, Ye ^a   Tham, Ivan W K ^b   Lu, Jiade Jay ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

chemotherapy; concurrent chemoradiation; nasopharyngeal carcinoma; radiotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ARTICLE; BRAIN NECROSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; XEROSTOMIA;

CHEMOTHERAPY; CONCURRENT CHEMORADIATION; NASOPHARYNGEAL CARCINOMA; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE; TAXOIDS;

EID: 84888006127     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28324     Document Type: Article

References (27)

1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317.
2. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21: 631-637.
3. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005; 97: 536-539.
4. Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005; 23: 8461-8468.
5. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005; 23: 6730-6738.
6. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23: 6966-6975.
7. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005; 23: 8636-8645.
8. Vermorken JB, Remenar E, van Herpen C, et al. EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704.
9. Posner MR, Hershock DM, Blajman CR, et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715.
10. Greene FL, Page DL, Fleming ID, et al. eds. American Joint Committee on Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
11. Wang TJC, Riaz N, Cheng SK, et al. Intensity-modulated radiation therapy for nasopharyngeal: a review. J Radiat oncol. 2012; 1: 129-146.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
13. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13: 163-171.
14. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002; 52: 1238-1244.
15. Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988; 6: 1401-1410.
16. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22: 4604-4612.
17. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998; 83: 2255-2258.
18. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 1350-1357.
19. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005; 23: 1118-1124.
20. Lee AWM, Ng WT, Chan OSH, et al. If concurrent-adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction-concurrent achieve better outcome? J Radiat Oncol. 2012; 1: 107-115.
21. Cooper JS, Lee H, Torrey M, et al. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the intergroup experience. Int J Radiat Oncol Biol Phys. 2000; 47: 861-866.
22. Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Strahlenther Onkol. 2005; 181: 223-230.
23. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 242-249.
24. Ekenel M, Kestin S, Basaran M, et al. Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2011; 47: 660-664.
25. National Institutes of Health. Induction chemotherapy and chemoradiotherapy in nasopharyngeal cancers (GORTEC-NPC2006). National Clinical Trial (NCT) 00828386. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00828386?term=GORTEC&rank=3. Accessed August 13, 2013.
26. National Institutes of Health. Induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: National Clinical Trial (NCT) 01245959. Available at: http://clinicaltrials.gov/ct2/show/NCT01245959?term= nasopharyngeal+carcinoma&rank=13. Accessed August 13, 2013.
27. Lin S, Lu JJ, Han L, Chen Q, Pan J,. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases [serial online]. BMC Cancer. 2010; 10: 39-47.